TonyRReidMD

Oncology • La Jolla, CA

Associate Professor of Medicine, UCSD

Join to view full profile

Dr. Reid is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Reid's full profile

Already have an account?

Office
3855 Health Sciences Dr
La Jolla, CA 92093
Fax+1 619-543-7277
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1997 - 1999
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1991 - 1994
Stanford University School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1993 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:San Diego Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Top Doctors:Southern California Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Join now to see all

Clinical Trials

Clinical Trial in Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver Start of enrollment: 2010 Jan 01
Terminated
Not Applicable
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Start of enrollment: 2011 Sep 01
Completed
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiother...
Marcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, Kyle Colvett, Vinita Takiar, Matthew Biagioli, Voichita Bar-Ad, Sharad Goyal, Brian Muzyka, Kenneth Niermann, Nacer ...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Jul 1
5 citations
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourt...
Tony R Reid, Nacer Abrouk, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Christopher Larson, Keola Beale, Susan J Knox, George Fisher> ;Clinical Colorectal Cancer. 2023 Mar 1
9 citations
RRx-001 and the "Right stuff": Protection and treatment in outer space.
Bryan Oronsky, Scott Caroen, Nacer Abrouk, Tony R Reid> ;Life Sciences in Space Research. 2022 Nov 1
11 citations
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot.
Bryan Oronsky, Brian Gastman, Anthony P Conley, Christopher Reid, Scott Caroen, Tony Reid> ;Cancers. 2022 Sep 27
6 citations
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christo...> ;Future Oncology. 2022 Sep 1
2 citations
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenogra...
Tony Reid, Bryan Oronsky, Nacer Abrouk, Scott Caroen, Pedro Cabrales> ;American Journal of Cancer Research. 2022 Jan 1
15 citations
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid> ;Journal of Cancer. 2022 Jan 1
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.
Xiaoning Guo, Xiaohui Wang, Sui Shen, Bryan Oronsky, Tony R Reid, Meaghan Stirn, Scott Caroen, Franck Brinkhaus, Nacer A Abrouk, Liandai Yang, Lianzong Wu, Zhongwen Yu> ;American Journal of Cancer Research. 2022 Jan 1
2 citations
Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.
Terese Catherine Hammond, Raymond C Lee, Bryan Oronsky, Tony R Reid, Scott Caroen, Tiffany M Juarez, Jaya Gill, Annie Heng, Santosh Kesari> ;International Medical Case Reports Journal. 2022 Jan 1
7 citations
AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomesresistance to PD-L1-immunotherapy.
Christopher Larson, Bryan Oronsky, Tony Reid> ;American Journal of Cancer Research. 2022 Jan 1
3 citations
A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoe...
Michael A. Turner, Siamak Amirfakhri, Hiroto Nishino, Thinzar M. Lwin, Thomas J. Savides, Tony R. Reid, Bernhard B. Singer, Robert M. Hoffman, Michael Bouvet> ;In Vivo. 2021 Jul 1
15 citations
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Bryan T. Oronsky, Xiaoning Guo, Xiaohui Wang, Pedro Cabrales, David J. Sher, Lou Cannizzo, Bob Wardle, Nacer Abrouk, Michelle Lybeck, S. Scott Caroen, Arnold L. Oronsk...> ;Journal of Medicinal Chemistry. 2021 May 27
9 citations
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Bryan Oronsky, Tony R. Reid, Pedro Cabrales> ;Journal of Drug Targeting. 2021 May 20
157 citations
A Review of Persistent Post-COVID Syndrome (PPCS).
Bryan T. Oronsky, Christopher A. Larson, Terese C. Hammond, Arnold L. Oronsky, Santosh Kesari, Michelle Lybeck, Tony R. Reid> ;Clinical Reviews in Allergy & Immunology. 2021 Feb 20
61 citations
A Review of Newly Diagnosed Glioblastoma.
Bryan Oronsky, Tony R. Reid, Arnold L. Oronsky, Navjot Sandhu, Susan J. Knox> ;Frontiers in Oncology. 2021 Feb 5
10 citations
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia.
Bryan Oronsky, Pedro Cabrales, Scott Caroen, Xiaoning Guo, Curtis Scribner, Arnold L. Oronsky, Tony R. Reid> ;Expert Opinion on Drug Metabolism & Toxicology. 2021 Jan 22
1 citations
A short discussion about the SARS-CoV-2 mRNA-1273 vaccine.
Bryan Oronsky, Harry E. Gruber, Wendy Reiners, Tony R. Reid> ;International Journal of Infectious Diseases. 2021 Jan 22
8 citations
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates wit...
Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan R. Baker, Sunmin Lee, Jane B. Trepel> ;Translational Lung Cancer Research. 2021 Jan 1
8 citations
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta.
Christopher Larson, Bryan Oronsky, Nacer E Abrouk, Arnold L. Oronsky, Tony R. Reid> ;American Journal of Cancer Research. 2021 Jan 1
9 citations
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.
Bryan Oronsky, Susan J. Knox, Pedro Cabrales, Arnold L. Oronsky, Tony R. Reid> ;Seminars in Oncology. 2020 Oct 1
5 citations
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making.
Christopher Larson, Bryan Oronsky, Sharad Goyal, Carolyn M. Ray, Farah Hedjran, Terese C. Hammond, Santosh Kesari, Scott Caroen, Michelle Lybeck, Vaughn E. Dobalian, A...> ;Biochimica Et Biophysica Acta. Reviews on Cancer. 2020 Aug 20
6 citations
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix.
Scott Caroen, Bryan Oronsky, Corey A. Carter, Michelle Lybeck, Arnold L. Oronsky, Tony R. Reid> ;Expert Opinion on Drug Delivery. 2020 Apr 30
90 citations
TGF-beta: a master immune regulator.
Christopher A. Larson, Bryan Oronsky, Corey A. Carter, Arnold L. Oronsky, Susan J. Knox, David J. Sher, Tony R. Reid> ;Expert Opinion on Therapeutic Targets. 2020 Apr 12
7 citations
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".
Bryan Oronsky, Corey A. Carter, Scott Caroen, Curtis Scribner, Arnold L. Oronsky, Tony R. Reid> ;Oncoimmunology. 2020 Apr 3
40 citations
Just eat it: A review of CD47 and SIRP-α antagonism.
Bryan Oronsky, Corey A. Carter, Tony R. Reid, Franck Brinkhaus, Susan J. Knox> ;Seminars in Oncology. 2020 Apr 1
Join now to see all

Lectures

ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

EpicentRx Doses First Subject in Phase III Lung Cancer Trial in ChinaOctober 7th, 2022
• News - Full StoryJuly 12th, 2022
New Phase 1 Clinical Trial for Pediatric CNS TumorsFebruary 24th, 2022
Join now to see all